MarketLens
Sign Up

What Happened with aTyr Pharma's Initial Phase 3 Trial

5 months ago
SHARE THIS ON:

What Happened with aTyr Pharma's Initial Phase 3 Trial

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma said the FDA aligned on a global Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease, using FVC as the primary endpoint. The company expects to start study-...
Stock News•1 months ago

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Dyne Therapeutics and Sarepta shares tumbled Tuesday after Novartis' muscle-wasting disorder treatment failed a trial, raising investor concerns about similar rare-disease therapies.
Stock News•3 months ago

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

Ionis and AstraZeneca's eplontersen failed the Phase 3 CARDIO-TTRansform trial in ATTR-CM, missing the primary composite endpoint of CV mortality and recurrent CV events versus placebo at Week 140.

Breaking News

View All →

Top Headlines

View More →
Stock News•26 minutes ago

Google parent Alphabet suffers nearly $500B Wall Street wipeout amid AI spending fears

Stock News•53 minutes ago

Amazon the Latest Mag 7 to Miss Q3 Estimates

Stock News•1 hour ago

20 Years of S&P 500 History Show: This Simple Strategy Is Only 8.3% Less Than "Perfect"

Stock News•1 hour ago

Microsoft Q1: Capex Shouldn't Scare You Due To Free Cash Flow

Stock News•1 hour ago

Microsoft Took The Balanced Approach To AI - Now It's The King